<?xml version="1.0" encoding="UTF-8"?>
<p id="para380">The chemoimmunotherapy combination assessed in the MARIETTA trial was active in every subgroup of secondary CNS lymphoma, with the best results shown in patients with CNS disease at initial lymphoma diagnosis (43% of the enrolled participants). The SCNSL1 trial has shown a 2-year progression-free survival of 45% in a group of 16 patients with CNS disease at initial diagnosis,
 <xref rid="bib11" ref-type="bibr">
  <sup>11</sup>
 </xref> and to our knowledge no other trials have focused on this crucial subgroup of patients. In our study, we report a 2-year progression-free survival of 71% (
 <xref rid="sec1" ref-type="sec">appendix p 11</xref>), an encouraging result considering that the 2-year progression-free survival for patients with diffuse large B-cell lymphoma without CNS involvement treated with R-CHOP is 70â€“75%.
 <xref rid="bib21" ref-type="bibr">
  <sup>21</sup>
 </xref>
</p>
